PF-08642534 vs Semaglutide (Wegovy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

PF-08642534

Developed by Pfizer

Phase 1 in Obesityundisclosed
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07731139 (registry estimate)

No aligned efficacy figure on record for this race.

Semaglutide (Wegovy)

Marketed by Novo Nordisk

Approved in Obesitypeptide
Reliable signal

NCT03548935 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.

Next expected readout: December 2026 · NCT05173714 (registry estimate)

Reported efficacy

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)

Result source: NCT03574597

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPF-08642534Semaglutide (Wegovy)
Body weight, % change—Not reported-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249
Weight loss of 5% or more—Not reported87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
Weight loss of 10% or more—Not reported70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711
Waist circumference, change (cm)—Not reported-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013

Body weight, % change

PF-08642534
—Not reported
Semaglutide (Wegovy)
-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249

Weight loss of 5% or more

PF-08642534
—Not reported
Semaglutide (Wegovy)
87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189

Weight loss of 10% or more

PF-08642534
—Not reported
Semaglutide (Wegovy)
70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711

Waist circumference, change (cm)

PF-08642534
—Not reported
Semaglutide (Wegovy)
-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

PF-08642534: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. PF-08642534: 0 of 4 rows · Semaglutide (Wegovy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSemaglutide (Wegovy)
Dropout rate
—2.4 mg weeklya
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
5.1%2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
11%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
3.2%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
2.9%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
16.7%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
15.3%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
14.4%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
0%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
4.6%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
0%
NCT04998136 · Phase 3 · registry result, not featured evidence
9.2%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
7.2%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
2.7%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
1.5%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
4.8%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
2.6%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
2%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
33.9%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
38.6%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
50%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
37.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%
NCT05302596 · Phase 2 · registry result, not featured evidence
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.9%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
8.7%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.9%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.7%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.4%
NCT04779697 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—2.4 mg weeklya
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
5.3%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
—
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
6.4%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
—Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
—
NCT04998136 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
—1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
1.8%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.3%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
5.4%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
—
NCT05302596 · Phase 2 · registry result, not featured evidence
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—
NCT04779697 · Phase 1 · registry result, not featured evidence
Serious AEs
9.8%2.4 mg weeklya
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
7.7%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
9.9%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
33.4%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
9.1%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
4.2%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
0%Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
1.2%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
8.1%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
7.3%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
12.9%
NCT04998136 · Phase 3 · registry result, not featured evidence
10%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
8.7%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
13.3%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
5.6%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
11.3%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
5%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
7%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.7%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
0%
NCT05302596 · Phase 2 · registry result, not featured evidence
12.5%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
4.3%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
12.7%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
5.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
4.9%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
7.8%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
12.6%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.1%
NCT04779697 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
2.4 mg weeklya
nausea 44.1% (placebo 17.4%)
diarrhoea 31.5% (placebo 15.9%)
vomiting 24.6% (placebo 6.6%)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
2.4 mg
diarrhoea 14.4% (placebo 7.1%)
nausea 14% (placebo 4.9%)
constipation 11.6% (placebo 6%)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 33.5% (placebo 9.2%)
diarrhoea 21.3% (placebo 11.9%)
vomiting 21.3% (placebo 2.7%)
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
covid-19 20.3% (placebo 20.3%)
nausea 18.1% (placebo 3.8%)
diarrhoea 10.6% (placebo 4%)
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 58.2% (placebo 22.1%)
constipation 36.9% (placebo 24.5%)
diarrhoea 36.1% (placebo 22.1%)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
nausea 73.6% (placebo 25%)
constipation 52.8% (placebo 16.7%)
diarrhea 37.5% (placebo 22.9%)
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
diarrhea 20% (placebo 22.9%)
constipation 10% (placebo 16.7%)
eructation 10% (placebo 6.3%)
NCT05548647 · Phase 4 · registry result, not featured evidence
2.4 mg
decreased appetite 19.3% (placebo 2.5%)
diarrhoea 18.6% (placebo 7.4%)
nausea 18% (placebo 2.5%)
NCT06041217 · Phase 3 · registry result, not featured evidence
7.2 mg
nausea 43.7% (placebo 13.4%)
diarrhoea 27.3% (placebo 12.9%)
vomiting 24.8% (placebo 7%)
NCT05646706 · Phase 3 · registry result, not featured evidence
nausea 37.6% (placebo 14.3%)
diarrhoea 27.7% (placebo 6.1%)
constipation 21.8% (placebo 16.3%)
NCT04998136 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 21.9% (placebo 8.9%)
covid-19 18.6% (placebo 22.2%)
constipation 11.9% (placebo 5.2%)
NCT05064735 · Phase 3 · registry result, not featured evidence
2.4 mg
covid-19 34.8% (placebo 30.4%)
nausea 29% (placebo 4.3%)
constipation 18.1% (placebo 0%)
NCT05040971 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 17.1% (placebo 2.6%)
covid-19 13.7% (placebo 15.4%)
diarrhoea 9.1% (placebo 3.8%)
NCT04788511 · Phase 3 · registry result, not featured evidence
2.4 mg
diarrhoea 26.1% (placebo 10.3%)
nausea 24.1% (placebo 7.1%)
upper respiratory tract infection 20.5% (placebo 20.6%)
NCT04251156 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 42.1% (placebo 17.9%)
vomiting 36.1% (placebo 10.4%)
diarrhoea 21.8% (placebo 19.4%)
NCT04102189 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 61.1% (placebo 22.4%)
constipation 38.9% (placebo 23.5%)
diarrhoea 27.8% (placebo 25.9%)
NCT04074161 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 53.3% (placebo 21.7%)
diarrhoea 34.9% (placebo 23.7%)
constipation 30.9% (placebo 11.2%)
NCT03693430 · Phase 3 · registry result, not featured evidence
2.4 mg
nasopharyngitis 26.6% (placebo 17.8%)
constipation 26.1% (placebo 3%)
nausea 17.6% (placebo 4%)
NCT03811574 · Phase 3 · registry result, not featured evidence
1.7 mg
nasopharyngitis 24% (placebo 17.8%)
diarrhoea 22% (placebo 5.9%)
constipation 19% (placebo 3%)
NCT03811574 · Phase 3 · registry result, not featured evidence
30 mg/kg + 1.0 mg
muscle spasms 64.3%
acne 55.4%
diarrhoea 44.6%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
30 mg/kg + 2.4 mg
muscle spasms 63.6%
acne 52.7%
diarrhoea 49.1%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 1.0 mg
muscle spasms 57.1%
diarrhoea 48.2%
acne 42.9%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 2.4 mg
muscle spasms 65.5%
nausea 61.8%
diarrhoea 52.7%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
gastrointestinal side effects: constipation 57.1%
gi side effects: nausea 28.6%
gi side effects: vomiting 14.3%
NCT05302596 · Phase 2 · registry result, not featured evidence
2.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 87.5% (placebo 12.5%)
vomiting 75% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2.0 mg + 2.4 mg
nausea 62.5% (placebo 12.5%)
constipation 50% (placebo 0%)
vomiting 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 50% (placebo 12.5%)
abdominal pain 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
nausea 44.7% (placebo 12.5%)
vomiting 31.9% (placebo 0%)
constipation 25.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0.4 mg
nausea 48% (placebo 17.6%)
diarrhoea 37.3% (placebo 11.8%)
constipation 23.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.4 mg (Fast Escalation)
nausea 48.5% (placebo 17.6%)
constipation 28.2% (placebo 4.4%)
diarrhoea 27.2% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg
nausea 41.7% (placebo 17.6%)
diarrhoea 26.2% (placebo 11.8%)
constipation 17.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg (Fast Escalation)
nausea 53.9% (placebo 17.6%)
diarrhoea 27.5% (placebo 11.8%)
vomiting 20.6% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.2 mg
nausea 43.7% (placebo 17.6%)
diarrhoea 34% (placebo 11.8%)
constipation 25.2% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.1 mg
nausea 41.2% (placebo 17.6%)
diarrhoea 24.5% (placebo 11.8%)
nasopharyngitis 22.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.05 mg
nausea 31.1% (placebo 17.6%)
diarrhoea 19.4% (placebo 11.8%)
nasopharyngitis 15.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
nausea 58.3% (placebo 20.8%)
abdominal pain 31.3% (placebo 20.8%)
diarrhea 29.2% (placebo 10.4%)
NCT04779697 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Wegovy)

Weight -15.6% (n=1306) vs -2.8% (n=655) placebo @ 68wk2.4 mg weekly
percent change · % of baseline
In-trial observation period
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 3 more results
-9.9% (n=404) vs -3.3% (n=403) placebo @ 68wk2.4 mg
In-trial observation period
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-16.5% (n=407) vs -5.8% (n=204) placebo @ 68wk2.4 mg
In-trial observation period
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-15.9% (n=144) vs -1.9% (n=128) placebo @ 104wk2.4 mg
In-trial observation period
NCT03693430 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 80.2% (n=1306) vs 27.8% (n=655) placebo @ 68wk2.4 mg weekly
event count · % of participants
In-trial observation period · Yes
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 1047 Participants as posted
show 3 more results
66.1% (n=404) vs 26.6% (n=403) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 267 Participants as posted
79.4% (n=407) vs 44.1% (n=204) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 323 Participants as posted
77.1% (n=144) vs 34.4% (n=128) placebo @ 104wk*2.4 mg
In-trial observation period · Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 111 Participants as posted
Weight Loss 10% 69.1% (n=1212) vs 12% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 838 Participants as posted
show 14 more results
79% (n=520) vs 20.4% (n=250) placebo @ 68wk*2.4 mg
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 411 Participants as posted
45.6% (n=388) vs 8.2% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 177 Participants as posted
75.3% (n=373) vs 27% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 281 Participants as posted
63.8% (n=207) vs 34.5% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 132 Participants as posted
60.4% (n=159) vs 11.5% (n=78) placebo @ 44wk*2.4 mg
Yes
NCT06041217 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
73.6% (n=129) vs 7.6% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 95 Participants as posted
63.4% (n=238) vs 10.3% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 151 Participants as posted
70.9% (n=117) vs 15.4% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
61.8% (n=144) vs 13.3% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 89 Participants as posted
68.5% (n=149) vs 13.2% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 102 Participants as posted
60.6% (n=193) vs 5% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 117 Participants as posted
41.8% (n=98) vs 5% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
82.4% (n=950) vs 20.5% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 783 Participants as posted
78% (n=100) vs 10.4% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 78 Participants as posted
Weight Loss 15% 50.5% (n=1212) vs 4.9% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 612 Participants as posted
show 13 more results
63.7% (n=520) vs 9.2% (n=250) placebo @ 68wk*2.4 mg
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 331 Participants as posted
25.8% (n=388) vs 3.2% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 100 Participants as posted
55.8% (n=373) vs 13.2% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 208 Participants as posted
44.9% (n=207) vs 14.1% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 93 Participants as posted
48.1% (n=129) vs 1.5% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 62 Participants as posted
34.5% (n=238) vs 6% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 82 Participants as posted
55.6% (n=117) vs 6.4% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 65 Participants as posted
52.1% (n=144) vs 7% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
52.3% (n=149) vs 5.4% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 78 Participants as posted
40.9% (n=193) vs 3% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 79 Participants as posted
24.5% (n=98) vs 3% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
66.5% (n=950) vs 7.6% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 632 Participants as posted
53% (n=100) vs 4.2% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
Weight Loss 20% 32% (n=1212) vs 1.7% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 388 Participants as posted
show 13 more results
13.1% (n=388) vs 1.6% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 51 Participants as posted
35.7% (n=373) vs 3.7% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 133 Participants as posted
23.7% (n=207) vs 4.5% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 49 Participants as posted
24.8% (n=129) vs 0% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 32 Participants as posted
14.3% (n=238) vs 1.7% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 34 Participants as posted
38.5% (n=117) vs 2.6% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 45 Participants as posted
36.1% (n=144) vs 2.3% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 52 Participants as posted
34.9% (n=149) vs 2.3% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 52 Participants as posted
19.7% (n=193) vs 2% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 38 Participants as posted
11.2% (n=98) vs 2% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
47.7% (n=950) vs 2.9% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 453 Participants as posted
47.7% (n=950) vs 33.3% (n=189) Semaglutide @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 453 Participants as posted
30% (n=100) vs 0% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 30 Participants as posted
Waist Circumference Change -14.1 vs -4.4 placebo cm @ 68wk2.4 mg weekly
absolute change · cm
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
-6.9 vs 3.2 placebo cm @ 68wk2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
-9.7 vs -4.3 placebo cm @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-15.2 vs -6.1 placebo cm @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-9.1 vs -2.4 placebo cm @ 44wk2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
-13.3 vs -5.9 placebo cm @ 68wk2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
-11.6 vs -2.8 placebo cm @ 52wk2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
-12 vs -2.8 placebo cm @ 52wk2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
-11.1 vs -3.8 placebo cm @ 44wk2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
-12.7 vs -0.5 placebo cm @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
-13.6 vs -2 placebo cm @ 68wk2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
-15.2 vs -4.3 placebo cm @ 104wk2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
-14.3 vs -4.5 placebo cm @ 52wk2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
-11.2 vs -1.8 placebo cm @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-10.2 vs -1.9 placebo cm @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-7.8 vs -1.8 placebo cm @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-7.6 vs -1.9 placebo cm @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-18 vs -5.6 placebo cm @ 72wk7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
-15.84 vs -10.57 semaglutide cm @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-19.03 vs -10.57 semaglutide cm @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-18.21 vs -10.4 semaglutide cm @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-21.26 vs -10.4 semaglutide cm @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-14.63 vs -10.57 semaglutide cm @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-16.55 vs -10.57 semaglutide cm @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-15.59 vs -10.4 semaglutide cm @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-18.1 vs -10.4 semaglutide cm @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
-4.8 vs -2.69 placebo cm @ 48wk1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
-12.31 vs -3.47 placebo cm @ 52wk0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-14.88 vs -3.47 placebo cm @ 52wk0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
-10.91 vs -3.47 placebo cm @ 52wk0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-11.06 vs -3.47 placebo cm @ 52wk0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
-11.02 vs -3.47 placebo cm @ 52wk0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-8.75 vs -3.47 placebo cm @ 52wk0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-6.11 vs -3.47 placebo cm @ 52wk0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-7.5 vs -1 placebo cm @ 104wk
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
-12 vs -3 placebo cm @ 44wk
NCT04998136 · Phase 3 · registry result, not featured evidence
SBP -7 vs -1 placebo mmHg @ 68wk2.4 mg weekly
absolute change · mmHg
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 22 more results
0 vs 5 placebo mmHg @ 68wk2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
-4 vs 0 placebo mmHg @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-6 vs -2 placebo mmHg @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-7 vs -4 placebo mmHg @ 44wk2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
-9 vs -1 placebo mmHg @ 52wk2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
-6.4 vs -1.1 placebo mmHg @ 52wk2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
-7 vs -2 placebo mmHg @ 44wk2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
-3 vs -1 placebo mmHg @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
-7 vs 5 placebo mmHg @ 68wk2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
-6 vs -1 placebo mmHg @ 104wk2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
-11 vs -5 placebo mmHg @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-12 vs -5 placebo mmHg @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-10 vs -4 placebo mmHg @ 72wk7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
-5.81 vs -1.58 placebo mmHg @ 52wk0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-10.26 vs -1.58 placebo mmHg @ 52wk0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
-6.41 vs -1.58 placebo mmHg @ 52wk0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-6.07 vs -1.58 placebo mmHg @ 52wk0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
-6.26 vs -1.58 placebo mmHg @ 52wk0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-5.76 vs -1.58 placebo mmHg @ 52wk0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-4.46 vs -1.58 placebo mmHg @ 52wk0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
-3.8 vs -0.6 placebo mmHg @ 104wk
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
-11 vs -1 placebo mmHg @ 44wk
NCT04998136 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning 2.3 vs 0.4 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in physical functioning score (SF-36)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 2 more results
1 vs -1.2 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.5 vs 1.7 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 - Role Physical 1.1 vs -0.2 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (role-physical score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Bodily Pain 0.5 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (bodily pain score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 General Health 2 vs -0.6 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (general health score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Vitality 0.7 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (vitality score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3

+ 146 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-08642534's landscape · Semaglutide (Wegovy)'s landscape